Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Kenvue Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $33.0B | |
|---|---|---|
| Revenue (ttm) | 15.4B | |
| Net income (ttm) | 1.7B | |
| EPS (ttm) | $0.85 | |
| Shares out | 1.9B | |
| P/E (trailing) | 22.7x | |
| P/E (forward) | 14.7x | |
| Dividend | $0.84 (4.34%) | |
| Volume | 6,839,244 | |
| Beta | 0.45 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B | +0.1% |
| Gross profit | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B | +1.1% |
| Operating income | $2.92B | $2.68B | $2.51B | $1.84B | $2.41B | -4.6% |
| Net income | $2.08B | $2.06B | $1.66B | $1.03B | $1.47B | -8.3% |
| EPS (diluted) | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 | -11.0% |
| EBITDA | $3.66B | $3.28B | $3.18B | $2.47B | $2.94B | -5.3% |
| R&D | $355.0M | $375.0M | $399.0M | $408.0M | $382.0M | +1.8% |
| SG&A | $5.48B | $5.63B | $6.14B | $6.33B | $6.09B | +2.6% |
Recent company headlines from major financial publishers.
The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).
In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 6.2% | $20.0 | $20.7 | $21.4 | $22.2 | $23.1 |
| 6.7% | $18.5 | $19.0 | $19.6 | $20.3 | $21.0 |
| 7.2% | $17.3 | $17.7 | $18.2 | $18.7 | $19.3 |
| 7.7% | $16.2 | $16.6 | $16.9 | $17.4 | $17.8 |
| 8.2% | $15.3 | $15.6 | $15.9 | $16.2 | $16.6 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |